Verseon Playing The Long Game To Level Up Drug Discovery
Executive Summary
Adityo Prakash, CEO and founder of Verseon, tells In Vivo more about his vision of re-routing the pharmaceutical industry with Verseon’s computational drug discovery technology. He also explains the company’s new subsidiary business, BlockRules, and how it fits into the biopharma world.
You may also be interested in...
NASH Backlash: Intercept Delay Raises Questions
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
Snapshot: Highlights From The First Six Months Of 2020
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
First Vaccine Approval For Janssen With Two-Dose Ebola Prophylactic
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
Need a specific report? 1000+ reports available
Buy Reports